J. Andrew Williams

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7

J. Andrew Williams, Barbara J. Ring, Varon E. Cantrell et al. · Drug Metabolism and Disposition · 2002 · 468 citations

Medicine, Biochemistry, Pharmacology +17

IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION

Andrew Rowland, David J. Elliot, J. Andrew Williams et al. · Drug Metabolism and Disposition · 2006 · 224 citations

Life Sciences, Biochemistry, Pharmacology +17

SILYBIN INACTIVATES CYTOCHROMES P450 3A4 AND 2C9 AND INHIBITS MAJOR HEPATIC GLUCURONOSYLTRANSFERASES

Chitra Sridar, Theunis C. Goosen, Ute M. Kent et al. · Drug Metabolism and Disposition · 2004 · 192 citations

Medicine, Biochemistry, Pharmacology +17

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz et al. · Applied immunohistochemistry & molecular morphology · 2018 · 189 citations · Full text

Medicine, Immunology, Oncology +17